The Dynamics of Indefinite Carryover and Excise Limitations in the Massachusetts Research and Development Tax Credit

Indefinite carryover in the context of the Massachusetts Research and Development (R&D) tax credit refers to the portion of the credit disallowed for use in a specific taxable year solely due to the 75% excise tax limitation, which is preserved for future use without expiration. This unique mechanism ensures that substantial long-term investments in innovation are not permanently forfeited due to annual tax caps, effectively decoupling the timing of research expenditures from the timing of tax liability realization.1

The complexity of the Massachusetts corporate excise system requires a nuanced understanding of how generated tax attributes are categorized, tracked, and utilized over multiple decades. The R&D credit, governed primarily by Massachusetts General Laws (M.G.L.) c. 63, § 38M, is designed to incentivize high-wage employment and technological advancement within the Commonwealth.1 However, unlike the federal research credit which generally provides a 20-year carryforward period, the Massachusetts framework bifurcates unused credits into two distinct “buckets”: a standard 15-year carryover and a more robust indefinite carryover.1 The latter is a direct consequence of the limitation imposed by § 38M(d), which prevents a corporation from using credits to offset more than 75% of its excise liability in excess of $25,000.3 This structural choice by the state legislature reflects a strategic balance between ensuring immediate state revenue and providing a durable, high-value incentive for industries with long development cycles, such as life sciences and aerospace.1 For tax practitioners and corporate financial officers, navigating these rules requires precise interaction with Department of Revenue (DOR) Technical Information Releases (TIRs), regulations such as 830 CMR 63.38M.1, and the intricate filing requirements of Schedule RC.3

The Statutory Architecture of the Massachusetts Research Credit

The foundation of the Massachusetts Research Credit is M.G.L. c. 63, § 38M, a statute that has evolved through significant legislative reforms intended to maintain the state’s competitive edge in the innovation economy.4 The credit is available to all business corporations subject to the corporate excise, provided they incur “qualified research expenses” (QREs) or make “basic research payments” for activities conducted within the geographical boundaries of Massachusetts.2

Defining Qualified Research and In-State Activity

Massachusetts largely aligns its definitions of research activity with the federal standards outlined in Internal Revenue Code (IRC) § 41.4 To qualify for the credit, expenditures must pass the “four-part test” adapted from federal law: the research must be technological in nature, intended for a permitted purpose (such as a new or improved product or process), aimed at eliminating uncertainty, and involve a process of experimentation.5

A critical differentiator for the Massachusetts credit is the “in-state” requirement. The expenses must be specifically attributable to research activity conducted in Massachusetts.2 This necessitates a rigorous proration of costs. If wages are paid to an employee who performs research both inside and outside the Commonwealth, only the portion of the wages corresponding to the number of days spent working in Massachusetts is eligible for inclusion in the credit calculation.13 This same logic applies to supplies and contract research expenses, where the location of the service performance or property use is paramount.2

Calculation Methodologies: The Choice of Regimes

Since the enactment of the Economic Development Act of 2014, corporations have been afforded two distinct methods for calculating their generated credit: the Traditional Method and the Alternative Simplified Credit (ASC) Method.4

The Traditional Method (§ 38M(a))

The traditional method provides a credit equal to the sum of 10% of the excess of QREs over a “base amount” plus 15% of basic research payments.4 The base amount is calculated using a complex “fixed-base ratio” and the average annual gross receipts of the taxpayer for the four preceding taxable years.3 Historically, the fixed-base ratio calculation was a significant hurdle for established companies, as it required historical data reaching back to the 1980s.12 Modern reforms have replaced this with a rolling “fixed-base ratio” determined by the ratio of QREs to gross receipts for the third and fourth taxable years preceding the credit year, capped at 16%.3

The Alternative Simplified Credit (ASC) Method (§ 38M(b))

The ASC was introduced to broaden the taxpayer base and simplify compliance.1 Modeled after the federal ASC in IRC § 41(c)(5), the Massachusetts version uses a three-year rolling average of QREs to determine the base.4 The credit amount is calculated as a percentage of the current year’s QREs that exceed 50% of the average QREs for the three preceding years.3

A taxpayer who did not have QREs in any of the three preceding years is granted a simplified credit of 5% of all current-year QREs.4 Once an election is made to use the ASC or the traditional method, it is generally binding for three taxable years to prevent taxpayers from “cherry-picking” methods based on short-term expenditure fluctuations.9

The Limitation Engine: Understanding § 38M(d)

While the calculation methods determine how much credit is generated, § 38M(d) determines how much credit can be used in any given year.3 This section of the law creates the legal mechanism that results in the indefinite carryover.1

The 75% Rule and the $25,000 Threshold

The credit used to reduce the corporate excise in a single year is subject to a progressive limitation based on the corporation’s total excise liability before credits.3 The limitation is structured as follows:

1. First $25,000 of Excise: 100% of this amount can be offset by the research credit.3
2. Excise in Excess of $25,000: Only 75% of this portion can be offset by the research credit.3

Additionally, the credit cannot reduce the corporation’s tax liability below the statutory minimum excise, which is currently $456.1 These limitations are applied to the total of the income and non-income measures of the corporate excise.9

Origins of the Indefinite Carryover Concept

The 75% limitation is essentially a “forced” tax payment. Even if a company has generated millions in research credits, the state requires that 25% of any tax liability over $25,000 must be paid in cash (or offset by other types of credits not subject to this rule).1 To ensure that this “disallowance” does not result in a permanent loss of the incentive, the law provides that the portion of the credit prohibited by this specific 75% rule can be carried forward indefinitely.1

This distinguishes it from credits that remain unused because they exceed the total tax liability or because they would reduce the tax below the $456 minimum.3 Such “standard” excess credits are subject to a 15-year carryover period, after which they expire.1

Administrative Guidance: Revenue Office Interpretations

The Massachusetts Department of Revenue (DOR) has issued extensive guidance to clarify the application of § 38M(d) and the resulting carryovers.2

Technical Information Release (TIR) 14-16

TIR 14-16 is one of the most critical documents for modern R&D credit administration.2 It provided the technical corrections necessary to implement the ASC and refined the definition of the “base amount” under the traditional method.10 Importantly, it reaffirmed that the 75% rule remains the primary constraint on credit utilization and that the “disallowed” portions from this rule are granted “unlimited status” for carryforward purposes.10

Regulation 830 CMR 63.38M.1 and Proposed Regulation 63.38M.2

The DOR’s official regulations provide the “Ordering Rules” that taxpayers must follow when they have multiple years of credits and different types of carryovers.9

The Ordering of Application

According to 830 CMR 63.38M.1 and reinforced in the instructions for Schedule RC, when a corporation has available credits, it must apply them in the following sequence to maximize their utility before expiration:

1. 15-Year Carryover Credits: These are applied first because they have an expiration date.3
2. Indefinite (Unlimited) Carryover Credits: These are applied second, as they do not expire.3
3. Current Year Credits: These are applied last, as they will then be categorized into the 15-year or indefinite buckets for the following year based on the current year’s excise limitation.3

This ordering priority is a key planning consideration. If a corporation applies current year credits before its 15-year carryovers, it risks the permanent loss of those older credits.9

Combined Reporting and Aggregate Group Dynamics

In Massachusetts, many corporations do not file in isolation but as part of a “combined group” under $M.G.L. c. 63, § 32B or as part of an “aggregated group” under § 38M.3 This adds a layer of complexity to the 75% limitation and the resulting indefinite carryover.3

The Aggregation Rule for the $25,000 Threshold

A single $25,000 threshold (the amount not subject to the 75% limit) must be shared among all members of an “aggregated group”.3 An aggregated group includes all members of a controlled group of corporations as defined by IRC § 41(f).4 Whether these members file separate returns or a combined report, they only get one $25,000 “full credit” bracket to split.3

The allocation of this $25,000 bracket is typically proportional to each member’s share of the total excise liability of the group.9 This prevents groups from creating multiple subsidiaries just to multiply the $25,000 threshold.9

Credit Sharing within Combined Groups

Under 830 CMR 63.32B.2, a member of a combined group that generates more R&D credit than it can use (after applying its own 75% limit) may “share” that excess credit with other members of the group.3 The receiving member can use the shared credit to offset its own excise, but it remains bound by its own 75% limitation.3

If a credit is shared and still cannot be used due to the 75% limit of the receiving member, the unused portion typically returns to the generating member to be carried over into the appropriate bucket (15-year or indefinite).3

The Impact of Ownership Changes (IRC Section 382)

For growth-stage technology and life sciences companies, ownership changes are common through successive fundraising rounds or acquisitions.28 These events trigger IRC § 382, which limits the utilization of pre-change tax attributes, including research credits.28

The Massachusetts Adjusted § 382 Limitation

Massachusetts adopts the logic of § 382 but requires a specific adjustment to the annual limitation to reflect state-level income.32

The “Adjusted § 382 Limitation” for Massachusetts purposes is calculated as:

$$\text{MA Limit} = \text{Federal } \S 382 \text{ Limit} \times \left( \frac{\text{MA Taxable Net Income}}{\text{Federal Taxable Income}} \right)$$

This calculation ensures that the state does not allow a disproportionate amount of credits to be used following a change in control.33 Any R&D credit carryover (indefinite or 15-year) that is disallowed by this adjusted § 382 cap for a particular year is carried forward to the next year, but the clock on 15-year credits continues to run.32 The indefinite carryover remains indefinite, but its “velocity” of use is severely throttled by the § 382 constraint.28

Industry-Specific Applications: Life Sciences and Climatetech

The Massachusetts legislature has tailored the R&D credit to support specific strategic sectors, leading to variations in how carryovers are managed.1

The Life Sciences Refund Election

Certified life sciences companies have a unique advantage: they can apply for a refund of their unused R&D credits.1 Under § 38M(j), if a company is certified by the Massachusetts Life Sciences Center (MLSC), it can elect to receive a refund of up to 90% of its unused credits instead of carrying them forward.5

This refundability effectively bypasses the 75% rule for those specific companies, providing immediate liquidity.1 However, if a company takes the refund, it cannot also carry the credits forward—the credits are “consumed” by the refund process.8 If a company is later “decertified,” it may face recapture of the refund, at which point the original carryover status (including the indefinite portion) may be restored on its books.8

The Climatetech Expansion (2024-2025)

The most recent significant change to the Massachusetts R&D landscape is the introduction of the Climatetech tax incentive program.36 Effective for tax years beginning on or after January 1, 2024, climatetech companies can receive a research credit similar to § 38M (10% on excess QREs, 15% on basic research payments).36

Crucially, the Climatetech research credit has a 5-year carryforward period.36 This is significantly shorter than the standard 15-year/indefinite split under the general R&D credit, emphasizing the legislature’s intent to drive rapid innovation and deployment in the green energy sector.39

Fiscal and Economic Context: State Expenditure Data

The Massachusetts Department of Revenue monitors the fiscal impact of these credits through its Tax Expenditure Reports.6 These credits represent a significant portion of the state’s total corporate tax incentives.6

The presence of the indefinite carryover means that the state carries a large “deferred liability” on its books representing credits earned by companies that have not yet had sufficient excise to utilize them under the 75% rule.1 For firms in the life sciences and tech sectors, this carryover is a multi-million dollar asset that provides long-term value, encouraging them to maintain their research facilities in-state even during years of low profitability or high investment.1

Comprehensive Multi-Year Calculation Example

To provide a clear understanding of how these rules apply in a real-world scenario, we will examine the five-year tax journey of “Quantum BioTech,” a fictional Massachusetts-based corporation.

Year 1: High Research Intensity

Quantum BioTech has a breakthrough year in research but generates no revenue.

• Massachusetts Excise: $456 (Minimum Excise) 1
• Research Credits Generated: $500,000

Utilization Analysis:

• The credit cannot reduce the excise below $456.2
• Therefore, $0 credit is used.
• Because the disallowance is due to the minimum excise and total lack of liability (not the 75% rule on excise above $25k), the entire amount is categorized as a 15-year carryover.3
• Year-End Status: $500,000 in 15-Year Carryover.

Year 2: First Commercialization

The company begins selling products and has a moderate tax bill.

• Massachusetts Excise (Pre-Credit): $20,000
• Research Credits Generated: $50,000
• Carryover from Year 1: $500,000 (15-yr)

Utilization Analysis:

• Excise Limitation: The first $25,000 of excise can be 100% offset.3
• Quantum BioTech uses $19,544 of its credits (reducing $20,000 to the $456 minimum).2
• Ordering Rule: It must use the Year 1 (15-year) credits first.17
• Carryover Calculation:

• Remaining Year 1 Credits: $500,000 – $19,544 = $480,456 (15-yr).
• New Year 2 Credits: $50,000 (disallowed because excise was under $25k, thus it’s a 15-yr carryover).3

• Year-End Status: $530,456 in 15-Year Carryover.

Year 3: Scaling Up

The company becomes highly profitable.

• Massachusetts Excise (Pre-Credit): $125,000
• Research Credits Generated: $100,000
• Carryover from Year 2: $530,456 (15-yr)

Utilization Analysis:

• Step 1: Calculate Max Credit Allowed under § 38M(d)

• 100% of first $25,000 = $25,000
• 75% of excess ($100,000) = $75,000
• Total Max Credit: $100,000.3

• Step 2: Apply Credits using Ordering Rules

• Apply $100,000 from the $530,456 (15-yr bucket).17

• Step 3: Categorize Unused Credits

• The unused Year 1/2 credits ($430,456) remain in the 15-year bucket.
• The new Year 3 credits ($100,000) were disallowed because the company hit its 75% cap.
• The amount disallowed by the cap is 25% of the excess over $25k, which is $25,000 ($100,000 *.25).3
• The remaining $75,000 of Year 3 credits were disallowed because the company ran out of “allowable” room.

• Year-End Status:

• 15-Year Bucket: $430,456 (Year 1/2) + $75,000 (Year 3) = $505,456.
• Indefinite Bucket: $25,000 (Year 3 portion disallowed by the 75% cap).

Year 4: Ownership Change

A large conglomerate acquires Quantum BioTech.

• Adjusted § 382 Limitation: $10,000.32
• Massachusetts Excise (Pre-Credit): $200,000.
• Carryovers: $505,456 (15-yr), $25,000 (indefinite).

Utilization Analysis:

• Even though the $\S 38M(d)$ rule would allow a credit of $25,000 + (75\% \text{ of } 175,000) = \$156,250$, the company is now bound by the much lower $\S 382$ limit of $10,000.32
• Quantum BioTech uses $10,000 from its 15-year bucket.17
• Year-End Status:

• 15-Year Bucket: $495,456.
• Indefinite Bucket: $25,000.

Comparison Table of Quantum BioTech’s Carryover Status

Strategic Considerations for Business Entities

The existence of indefinite carryover creates specific strategic imperatives for businesses operating in Massachusetts.1

Valuation and Due Diligence

During mergers and acquisitions, the “quality” of a target’s tax attributes is a significant factor in valuation.28 R&D credits with indefinite status are essentially permanent reductions in future effective tax rates, making them more valuable than NOLs or 15-year credits that may expire during a downturn or a lengthy development phase.1 Buyers should carefully audit the target’s Schedule RC and past returns to ensure that the indefinite vs. 15-year buckets have been calculated correctly in accordance with § 38M(d).5

ASC Election Stability

While the Alternative Simplified Credit (ASC) offers a higher generation rate for many companies (10% on the excess over 50% of the three-year average), its rolling nature means that if a company’s R&D spending stays flat or declines, the credit generated will eventually shrink to zero.1 Companies with consistent research spending may find the traditional method—with its rolling fixed-base ratio—more beneficial for building a large “bank” of indefinite carryover credits that can be used once the company reaches peak profitability.1

Management of “Flow-Through” Entities

It is important to note that the R&D credit does not flow through to individual shareholders in S-Corporations at the entity level for the income measure of the corporate excise.1 The credit is applied against the corporate excise due under Chapter 63.3 For unincorporated entities like partnerships and LLCs, the credits are attributed to the owners and taken into account in determining their personal tax liability under Chapter 62.1 This distinction in entity structure determines who ultimately “owns” and tracks the 15-year and indefinite carryover buckets.1

Conclusion

The Massachusetts Research and Development tax credit is a powerful economic development tool that hinges on the legislative recognition of the long-term nature of innovation.1 The provisions for indefinite carryover for credits disallowed by the 75% rule under $M.G.L. c. 63, § 38M(d) provide a critical safety net for high-investment firms, ensuring that their tax benefits are preserved regardless of short-term excise limitations.1 By meticulously navigating the DOR’s Technical Information Releases and regulatory ordering rules, corporations can optimize their tax positions and maintain a perpetual asset that supports continued research within the Commonwealth.1 As Massachusetts expands its innovation incentives to include climatetech and a broader range of financial institutions, the principles of § 38M and its unique carryover structure will remain a vital component of the state’s fiscal and industrial landscape.14

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/